上海招聘

JW’s world-class clinical team is seeking a talented and highly motivated Sr. Scientist (title commensurate with experience) to join our Translational Research group. In this role you will design and implement biomarker strategies to characterize the distribution, efficacy and mechanism of actions of CAR-T and TCR-T drug products in preclinical models and early clinical trials in solid tumors and malignant hematology. In addition, you will lead the translational biomarker collaboration with some of the world’s best oncology companies and JW’s biotech partners in the USA.  

1.      Design and implement translational strategies to characterize the solid tumor microenvironment (TME), tumor infiltration lymphocytes (TIL), and therapeutic T-cell products in order to identify potential biomarkers associated with PK and clinical outcomes

2.      Design and implement biomarker strategies to elucidate the mechanisms of actions (MOA) of therapeutic T-cell products and their combinations, and to correlate these mechanisms into clinical benefits

3.      Manage the collaborative activities with both JW’s international alliances and domestic vendors to generate and test biomarker hypothesis with cutting-edge assays

4.      Collaborate cross-functionally with Medical Science, Clinical Operations, Bioanalysis, Preclinical Pharmacology, Process Development, and Analytical Development teams in the development and proof-of-concept of hypothesis-based clinical biomarker plans

5.      Provide technical leadership in the transfer of biomarker assays to bioanalysis group for clinical trials using a broad range of technologies

6.      Continuously evaluate new technologies for clinical immune-oncology and T cell functional characterization while implementing and refining translational and biomarker strategies to maintain JW on the cutting edge of CAR-T and TCR-T cell-therapies.

Qualification:

1. Ph.D. in immunology or similar discipline with 1+ years of directly relevant experience; Or MS with at least 3+ years in immuno-oncology biomarkers in an industry setting; Candidates without a PhD will be considered if they have commensurate experience
2. Hands on experience in MOA based biomarker identification and clinical implementation in immuno-oncology is preferred; experience with cell therapies is highly desirable
3. Expertise in human T cell biology, in vitro and in vivo functional assays utilizing human T cells; experience with CAR-T, TCR-T, or a related cell therapy platform is highly desired
4. Experience in biomarker assays using a broad range of technologies including ligand binding immunoassays, assays of T cell function, multi-parametric flow cytometry, multiplex IHC and/or ISH assays, real-time PCR and next generation sequence analysis
5. Highly effective collaboration in a matrix environment, written/verbal communication in Chinese and English, and interpersonal skills
6. Can-do attitude and ambition to be the best in the field of cancer cell therapy

药明巨诺是一家专注于细胞免疫治疗、处于临床阶段的创新型生物科技公司，站在巨人的肩膀上，充分结合了美国巨诺公司国际领先的技术优势以及药明康德集团强大的本土经验。

定位与愿景：
致力于以创新为先导，成为细胞免疫治疗引领者
 - 对患者：用最前沿的细胞免疫治疗技术、高品质的产品，造福中国及全球患者
 - 对行业：与国内外合作伙伴携手开展多方位合作，共建中国细胞免疫治疗的行业规范与生态系统，打造国际领先的细胞免疫治疗技术创新平台